Connor, Clark & Lunn Investment Management Ltd. Olema Pharmaceuticals, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2024 Aug 09, 2024	SELL	$8.73 - $13.99 $207,381 - $332,332	-23,755 Reduced 45.75%	28,167 $304,000
Q1 2024 May 09, 2024	BUY	$10.95 - $16.62 $568,545 - $862,943	51,922 New	51,922 $587,000

Others Institutions Holding OLMA

# of Institutions

136

Shares Held

58.7M

Call Options Held

141K

Put Options Held

23.1K

Bvf Inc San Francisco, CA

9.14M
Shares

$46 Million
3.47% of portfolio
Paradigm Biocapital Advisors LP New York, NY

5.5M
Shares

$27.7 Million
2.37% of portfolio
Deep Track Capital, LP Greenwich, CT

4M
Shares

$20.2 Million
1.76% of portfolio
Black Rock Inc. New York, NY

4M
Shares

$20.2 Million
0.0% of portfolio
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct

3.69M
Shares

$18.6 Million
0.12% of portfolio

View Full List

About Olema Pharmaceuticals, Inc.

Ticker OLMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,419,600
Market Cap $204M
Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, local...

More about OLMA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account